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Purpose: The efficacy of currently available topical hemostatic agents requires the forma- 
tion of fibrin generated from circulating blood. Fibrin sealant, which is prepared from 
high concentrations of thrombin and fibrinogen, has been used in liquid form to promote 
hemostasis during vascular surgery. In a blinded, randomized, placebo-controlled fash- 
ion, we evaluated a dry dressing of purified, viral-inactivated human fibrinogen and 
human thrombin in a large animal model of arterial injury. 
Methods: Dressings were prepared by application of a layer of lyophilized human fibrin 
sealant or immunoglobulin G (IgG, control) to a silicone backing material. Six anesthe- 
tized female Yorkshire pigs (16 to 27 kg) received bilateral, 4 mm longitudinal femoral 
arteriotomies after surgical exposure of the arteries. The arteriotomies were not closed. In 
each animal a fibrin sealant dressing was applied to one artery and a control dressing to 
the other. Each dressing was secured on the arteriotomy by a mechanical device. After 
application of the dressings, blood flow was restored to each limb for 1 hour. The 
compressive device was released for 5 seconds at intervals of 15 minutes to assess 
hemostasis. Blood flow was measured istal to each arteriotomy with a dual-channel 
flowmeter to adjust equal bilateral compression. 
Results: Blood loss (mean 4-' SEM) was significantly less from the arteriotomy treated 
with the fibrin-based ressing compared with the control dressing (4.9 4- 4.0 ml versus 
82.3 - 11.1 ml; p = 0.0005). Complete hemostasis was achieved at the first 15-minute 
interval in five of six arteriotomies treated with fibrin sealant and in none of the six 
control arteriotomies during i hour of assessment (p = 0.03). Blood flow through each 
femoral artery at baseline was the same in both treatment and control arteries (fibrin 
sealant, 114.2 -.+ 17.4 ml/min; control, 106.7 4-16.5 ml/min; p = 0.24) and was not 
significantly different throughout the experiment. 
Conclusions: Fibrin-based ressings provide effective hemostasis n a large animal model 
of arterial injury. Further development of these dressings will address optimal formula- 
tion and configuration for clinical use. Our results uggest that fibrin-based dressings will 
be effective in promotion ofhemostasis in arterial bleeding, without compromising blood 
flow. (J Vasc Surg 1997;26:274-80.) 
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All currently available topical hemostatic agents 
(oxidized cellulose, purified gelatin, and bovine col- 
lagen) serve as mechanical templates on which 
thrombus forms and are limited in efficacy because of 
their lack of any inherent coagulation mechanism. 
Fibrin sealant, on the other hand, mimics the final 
step in the coagulation cascade and has been used to 
promote hemostasis n a variety of  vascular surgical 
procedures ~ ~0 and in human splenic trauma. ~ 1 Fibrin 
sealant, which is produced by the simultaneous appli- 
cation of thrombin and fibrinogen, is flexible, ab- 
JOURNAL OF VASCULAR SURGERY 
Volume 26, Number 2 Jackson et al. 275 
sorbed in days tO weeks, can be applied on a bleeding 
surface, and produces an effective hemostatic 
seal. 12q4 Unfortunately, there is no commercially 
available fibrin sealant in the United States. Use of 
fibrin sealant, or fibrin glue, has therefore been lim- 
ited to instances when significant bleeding warrants 
patient exposure to pooled cryoprecipitate as the 
fibrinogen substrate or in centers with fibrin sealant 
blood bank programs that use autologous or single- 
donor fibrinogen. However, this latter solution re- 
quires a planned elective use in which the need for 
fibrin sealant can be anticipated and blood bank 
support exists. Recently formulations of liquid fibrin 
sealant hat use solvent-detergent treatment and 
other methods of viral inactivation have been devel- 
oped and are undergoing clinical trials, i  Fibrin seal- 
ant as a dry dressing composed of a mixture oflyoph- 
ilized human fibrinogen and thrombin could provide 
surgeons with a ready-to-use material of superior 
hemostatic efficacy that poses minimal risk of trans- 
mission of blood-borne disease. In Europe, similar 
dressings are available or are under development in 
clinical and preclinical trials. The purpose of this 
study was to evaluate, in a blinded placebo-con- 
trolled manner, the hemostatic efficacy of a prototype 
lyophilized powder fibrin sealant-based dressing in a 
large animal model of arterial injury. An additional 
objective of this study design was to determine 
whether the direct application of a fibrin sealant- 
based dressing on the external surface of a large 
artery laceration acutely compromises distal arterial 
blood flow. 
MATERIAL AND METHODS 
Experimental design and technique. Animal 
care was in accordance with the Principles of Labora- 
tory Animal Care (formulated by the National Soci- 
ety for Medical Research) and the Guide for the Care 
and Use of Laboratory Animals (National Institutes 
of Health Publication No. 86-23, revised 1985), and 
all applicable Walter Reed Army Institute of Re- 
search guidelines and standard operating procedures. 
Bilateral femoral arteriotomies (4 mm in length) 
were made after surgical exposure in eight anesthes- 
tized female Yorkshire pigs (weight, 16-27 kg). The 
arteriotomies were not closed. Two animals were 
excluded from the study. In one, induction of gen- 
eral anesthesia resulted in death before the surgical 
protocol was begun. In the other, postmortem ex- 
amination showed that the fibrin sealant dressing has 
become dislodged on the proximal part of the femo- 
ral artery and was not in contact with the femoral 
arteriotomy. Fibrin sealant-based (Fibriseal, Ameri- 
can Red Cross, treatment group) and immunoglob- 
ulin G (IgG; PolyGam, American Red Cross, placebo 
control) dressings oflyophilized protein were placed 
on the arteriotomies in a randomized blinded fash- 
ion, so that each animal served as its own control. 
Ultrasonic flow probes were placed on each femoral 
artery distal to the site of injury and were connected 
to a dual-channel flowmeter (Transonic Systems, 
Inc., Ithaca, N.Y.). The dressings were held in place 
with a mechanical device (Compressar, Instrumed- 
ics, Hillsboro, Ore.) that is used to compress the 
groin after arteriography in patients. Proximal and 
distal vascular control was then released. Sufficient 
compression tostop the bleeding but to allow flow 
through the femoral artery was applied. Blood 
pressure was continuously monitored with a ca- 
rotid artery catheter. Intravenous normal saline 
solution was given at a maintenance dose and at 
3:1 volume to replace measured blood loss at 15- 
minute intervals. 
The time length of the experiment was 1 hour 
after estoration of blood flow in the injured femoral 
arteries. Compression on the femoral arteries was 
released at 15-minute intervals for assessment ofhe- 
mostasis. If hemostasis was complete, the compres- 
sion was removed for the duration of the experiment. 
If bleeding was noted, compression was reapplied in 
5 seconds and the blood was removed from the 
wound with surgical sponges. In either case, the 
dressing remained on the arteriotomy. In animals 
where hemostasis was initially complete and bleeding 
from the arteriotomy occurred later in the experi- 
ment, compression was reapplied to the dressing. 
Blood loss was measured in grams with use of the 
corrected weight of the sponges measured on an 
analytical balance (PB8001, Mettler-Toledo Inc., 
Hightstown, N.J.). The specific gravity of blood was 
assumed to be 1.0 gm/ml. At the end of the experi- 
ment, the animal was ldlled. 
Fibrin sealant-based ressing. We investi- 
gated a prototype fibrin sealant dressing (Fibriseal) 
developed by the Jerome Holland Laboratory of the 
American Red Cross (Rockville, Md.). The pro.duct 
consists of three components: purified human fibrin- 
ogen, which contains trace amounts of factor XIII 
and fibronectin; purified human thrombin; and cal- 
cium chloride. Virus inactivation was performed with 
solvent-detergent treatment. 16 The fibrin sealant 
dressing consists of a 3 × 2.5 cm silicone bacldng 
(DermaSof, McGhan Medical Corporation) on 
which lyophilized fibrinogen and thrombin with 
calcium chloride are applied. The concentrations 
per square centimeter of dressing are 15 mg fibrin- 
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Fig. l. Boxplots 26 of blood loss from the fibrin sealant- 
treated artery and the control artery. The top of the box is 
the third quartile (Q3), and the bottom of the box is the first 
quartile (Q1). The horizontal ine through the box repre- 
sents the median. The vertical ines extend from the box to 
the adjacent values. The adjacent values are the lowest and 
highest observations that are still inside the region defined 
by the following l imits: lower limit: Qa - 1.5 (Q3 - Q1); 
upper limit: Q3 + 1.5 (Q3 - Q1). Oudiers are points 
outside of the lower and upper limits and are marked by 
asterisks (*). 
ogen, 36 units thrombin, and 3.6 mg calcium 
chloride. 
IgG control dressing. The control dressing, 
which was visually identical to the fibrin sealant 
dressing, was composed of lyophilized human IgG 
(PolyGam, American Red Cross) and calcium chlo- 
ride placed on a silicone backing (DermaSof, 
McGhan Medical Corporation). The control 
dressing had the same amount of material (milli- 
grams per square centimeter) as the fibrin sealant 
dressing. 
Data  analysis. The primary end point of this 
study was quantity of blood loss from the injured 
femoral arteries during the 1-hour experiment. Vol- 
ume of  blood loss from the arteries in the two groups 
was treated as a paired continuous variable and was 
expressed in milliliters _+ SEM. Differences between 
the two groups were compared with use of a paired t
test. The secondary end point of the study was the 
presence or absence of complete hemostasis 15 min- 
utes after application f  dressings to the injured fem- 
oral arteries. Complete hemostasis was recorded as a 
paired, dichotomous categorical variable. Differences 
between the two groups were analyzed with use of 
McNemar's test for paired data. A one-sided com- 
parison was performed because a treatment (fibrin 
sealant dressing) was compared with a placebo con- 
trol (IgG) with no known hemostatic properties. 
Blood flow distal to the femoral arteriotomy was 
recorded as a paired continuous variable. The differ- 
ence in blood flow between the treatment and con- 
trol arteries was assessed at each 5-minute time inter- 
val and described as the mean + SEM. The two mean 
values (treatment and control) were compared with a 
paired t test. Significance was interpreted at the p < 
0.05 level. 
RESULTS 
Blood loss. Mean blood loss from the fibrin 
sealant dressing-treated arteries was 4.9 -+ 4.0 ml. 
Blood loss was significantly higher in the control 
group (82.3 --+ 11.1 ml; p = 0.0005; Fig. 1). The 
blood loss from the fibrin sealant-treated arteries was 
primarily from one animal that did not have com- 
plete hemostasis at 15 minutes. In this animal the 
blood loss was 24.7 ml, which was less than the 
blood loss from the contralateral control artery (93.4 
ml). Even in the one fibrin sealant dressing treatment 
failure, there was temporary hemostasis, ranging 
f rom 30 to 92 seconds, at three of the four 15- 
minute intervals before bleeding resumed. 
Hemostat ic efficacy. At the first 15-minute in- 
terval when the dressings were removed from the 
femoral arteriotomy, complete hemostasis was ob- 
served in five (5/6)  fibrin sealant-treated arteries, 
and in none (0/6)  of the control-treated arteries 
(p = 0.03, McNemar's test for paired data). In all five 
arteries successfully treated with the fibrin sealant 
dressing, complete hemostasis persisted throughout 
the remaining 45 minutes of  the 1-hour experiment, 
without the need for continued or subsequent com- 
pression of the dressing or artery. In contrast, the 
IgG control-treated arteries continued to bleed pro- 
fusely at each 15-minute interval of the experiment 
when the Compressar device was temporarily re- 
moved for 5 seconds. Between all 15-minute inter- 
vals the control dressings required mechanical com- 
pression with the Compressar device to achieve 
temporary hemostasis. The maximum systolic blood 
pressure in animals successfully treated with the fi- 
brin sealant dressing was 140 mm Hg. In the one 
treatment failure, the maximum systolic blood pres- 
sure was 110 mm Hg. 
A consistent observation throughout the study 
was that in the fibrin sealant-treated arteries, astable 
"sheet" of  material (presumably fibrin) of the exact 
dimension of the dressing was deposited on the sur- 
face of the injured artery. This was observed after the 
conclusion of the experiment when the silicone back- 
ing material was removed from the wound. When the 
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Fig. 2. Femoral artery blood flow measured distal to the site of vessel injury for both groups. 
silicone backing was removed from the control ar- 
tery, no such layer was observed. 
Blood flow. Initial baseline blood flow was 
114.2 +- 17.4 ml/min in the treatment arteries and 
106.7 + 16.5 ml/min in the control arteries (p = 
0.24). During the 1-hour experiment, blood flow 
tended to be slightly higher in the fibrin sealant- 
treated arteries than in the control-treated arteries 
(Fig. 2). The mean difference in blood flow was 
10.8 -+ 7.1 ml/min higher in the fibrin sealant- 
treated arteries (p = 0.19). In five of six animals 
blood flow dropped below baseline for both the 
fibrin sealant-treated arteries and the control-treated 
arteries. The average flow in the fibrin sealant- 
treated arteries was 77.9% of baseline (p = 0.025). 
Similarly, the average flow for these same animals in 
the control-treated arteries was 67.1% of baseline 
(p = 0.028).  
DISCUSSION 
This study confirms and extends the r cent non- 
blinded experiment in a porcine arterial injury model 
in which the authors howed that a gauze bandage to 
which lyophilized fibrinogen and thrombin of bovine 
origin was added resulted in an 84% reduction in 
blood loss compared with the gauze alone. 17 In the 
present study, which was performed in a blinded 
fashion, the dressing was precoated with a highly 
purified, virally inactivated human fibrinogen and 
human thrombin (112 mg fibrinogen and 270 units 
thrombin). The fibrinogen and thrombin quantifies 
were only 19% and 5% of the quantities used in the 
previous study and yet were quite efficacious when 
applied according to the experimental model. The 
measurements of femoral artery blood flow in this 
study indicate that hemostasis was not the result of 
mechanical compression or occlusion of the injured 
artery. 
This study also shows that arterial flow to the 
lower limbs was not compromised by the increased 
hemostatic activity produced by the application of 
the fibrin sealant-based ressing when compared 
with the control dressing. Any potential for fibrin 
sealant-based dressings to cause intraluminal throm- 
bosis would limit the applicability of such dressings 
in clinical use. This has been investigated previously 
in an animal model in whcih liquid fibrin glue was 
applied to the suture holes of a polytetrafluoroethyl- 
ene patch angioplasty, and no evidence ofintralumi- 
nal fibrin was observed uring histologic studies, is 
Our results show that femoral artery flow is not 
compromised by the use of a fibrin sealant dressing, 
which indicates that no significant intraluminal 
thrombosis occurs. However, as fibrin sealant-based 
dressings are developed and become available, they 
could be used in settings such as vascular trauma, 
where a large vessel defect would introduce this po- 
tential risk. Although our data would indicate that 
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femoral artery thrombosis does not occur, additional 
studies that include an assessment of intraluminal 
histology or vascular imaging would be required to 
more thoroughly address this issue. 
Observations from this study and the model de- 
velopment that preceded it would suggest that the 
fibrin sealant dressing must be placed directly on the 
arteriotomy for effective hemostasis. A consistent 
finding was that the fibrin sealant from the dressing 
leaves a "patch" where it is applied, suggesting that 
there is no spread or diffusion of the material in this 
configuration. In the one animal in which incom- 
plete hemostasis was noted with fibrin sealant reat- 
ment, we speculate that the dressing might have only 
partially covered the arteriotomy. In the previously 
described model reported by Larson et al., 17 hemor- 
rhage was adequately controlled from longer arteri- 
otomies (13 mm) by use of greater amounts of fi- 
brinogen and thrombin. The clinical significance of 
this issue is that the surface area of fibrin sealant 
dressings would need to be fabricated large enough 
to completely cover a bleeding wound or vascular 
structure. 
The primary clinical use of fibrin sealant is as an 
adjunct to hemostasis during surgery, particularly 
cardiac and vascular surgery. In a randomized, pro- 
spective, multicenter U.S. trial that evaluated the use 
of a commercially prepared fibrin sealant for hemo- 
stasis during reoperation for cardiac surgery, success- 
ful hemostasis was achieved within 5 minutes in 
92.6% of those treated with fibrin sealant compared 
with only 12.4% in those treated with conventional 
topical hemostatic agents? ° In this study a commer- 
cially prepared fibrin sealant ( IMMUNO AG, Vi- 
enna, Austria) with a fibrinogen concentration of90 
mg/ml was used. A recently published clinical trial 
evaluated the use of fibrin sealant prepared by the 
Scottish National Blood Transfusion Service 
(SNBTS) to prevent suture hole bleeding during 
carotid endarterectomy? 9 Fibrin sealant prepared by 
the SNBTS has a fibrinogen concentration of 40 
mg/ml. In this study, patients undergoing carotid 
endarterectomy closure with polytetrafluoroethylene 
patch angioplasty were randomized to receive ither 
fibrin sealant or nothing on the suture holes. Patients 
treated with fibrin sealant had a significant reduction 
in time to hemostasis (5.5 versus 19 minutes; p < 
0.005). 
Fibrin sealant prepared by Baxter Healthcare 
(Hyland Division, Glendale, Calif.) in cooperation 
with the American Red Cross is being used in a 
muhicenter clinical trial to evaluate hemostatic effi- 
cacy when applied to extracorporeal membrane oxy- 
genation carotid artery cannulation sites in neo- 
nates) s Preliminary results from a midpoint analysis 
showed differences in the number of patients who 
sustained a blood loss of more than 40 ml within 4 
hours (8.6% of control subjects and 2.5% of the 
treatment group). The average blood loss for 24 
hours was significantly lower in the treatment group 
(8.3 L/gin) than in the control subjects (14 ml/kg). 
Forty-two percent of the treatment group had no 
blood loss, compared with only 17% of control sub- 
jects. 
In these studies the fibrin sealant was prepared 
from the reconstitution of the constituent products, 
an often time-consuming process that can limit the 
utility and ease of use. Fibrin glue prepared in most 
U.S. centers cannot be used until the cryoprecipitate 
has thawed and has been made available from the 
blood bank. Even the commercial preparations, 
which have not yet received approval from the U.S. 
Food and Drug Administration, require the reconsti- 
tution oflyophilized proteins in a warming bath. The 
material used in this study represents an effort to 
develop a ready-to-use, fibrin sealant-based topical 
agent. At least one such product is under commercial 
development and is available for clinical use in Eu- 
rope. TachoComb (Hafslund Nycomed Pharma, Vi- 
enna, Austria) is an absorbable wound dressing that 
consists of a collagen backing coated with dry fibrin 
sealant, and it is currently licensed in Sweden, Nor- 
way, Denmark, Belgium, The Netherlands, and Lux- 
embourg. 2° 
Our results suggest hat fibrin sealant dressings 
have potential for use in the early management of
battlefield wounds. Preliminary observations of the 
use of this dressing in a ballistic injury model are 
encouraging (MacPhee MJ, Drohan WN. Unpub- 
lished data, July 1995). Although the results of the 
present study suggest hat a fibrin sealant dressing 
alone can effectively produce hemostasis n a large 
artery injury, additional experiments are necessary to 
investigate the durability of hemostasis achieved in 
this manner. We recommend the use of fibrin sealant 
dressings only as an adjunct to initial hemostasis; 
definitive vascular repair would follow once an in- 
jured patient (or soldier) could be transported to a 
facility where surgical capability exists. This is partic- 
ularly relevant in the military trauma environment, 
where delays in the definitive management of battle- 
field injuries may occur. 
The previously described studies, as well as our 
own, suggest that fibrin sealant prepared from higher 
concentrations of fibrinogen than those available in 
cryoprecipitate, asused in operating rooms in the 
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United States, has considerable potential as an ad- 
junct to hemostasis during vascular surgery. The fi- 
brinogen concentration n cryoprecipitate is rela- 
tively low, generally in the range of 10 mg/ml.  21 In 
contrast, the fibrin sealant dressing evaluated in this 
study contained 112.5 mg of fibrinogen in a small 
(3 × 2.5 cm) thin layer of topical fibrinogen com- 
plex. Given the equal volume of bovine thrombin 
that would be required to reconstitute a cryoprecip- 
irate-based fibrin "glue," a 22 ml total volume would 
be necessary to match the fibrinogen concentration 
contained in our study dressing. The small quantity 
of lyophilized fibrinogen-thrombin mixture used in 
our study dressing was typically fully moistened with 
1 to 2 ml of blood from the wound to which it was 
applied. 
There are other potential applications for a fibrin 
sealant dressing or topical agent during elective vas- 
cular surgery. One example is its potential use for 
suture hole and retroperitoneal bleeding during tho- 
racoabdominal neurysm repair. Another possible 
use is for control of nonsurgical bleeding during 
procedures when continued anticoagulation is neces- 
sary. Human fibrin sealant (Baxter Hyland) has been 
obtained for compassionate use as a hemostatic agent 
during coronary artery bypass surgery in a patient 
,with heparin-induced thrombocytopenia anticoagu- 
lated with heparinoid (Org 10172, Organon Int, 
Oss, The Netherlands). 22 
The fibrin sealant dressing used in this study is a 
prototype only. Once additional preclinical testing 
establishes the optimal configuration(s) for clinical 
use, randomized clinical trials should be performed 
to confirm claims of efficacy. A fibrin sealant dressing 
or lyophilized fibrin sealant alone could be used as an 
adjunct o surgical hemostasis. 
Because commercially available topical thrombin 
solutions are of bovine origin and because some 
commercial preparations ofbovine thrombin contain 
high concentrations of bovine factor V, there are 
additional problems associated with the use of 
"homemade" fibrin glue. Antibodies directed against 
bovine factor V that cross-react with human factor V 
have been detected after use of bovine thrombin and 
have been documented to cause factor V deficiency 
of sufficient severity to cause bleeding complica- 
tions. 23-25 Detection of the anti-factor V antibodies 
and anti-thrombin a tibodies has been reported after 
use of bovine thrombin in fibrin sealant prepara- 
tions. 2s Because commercially prepared fibrin sealant 
is made from purified human fibrinogen and throm- 
bin, these immunologic onsequences should be 
eliminated. 
In summary, a prototype fibrin sealant dressing 
was effective in the promotion of hemostasis in a 
large animal model of femoral artery injury. No sig- 
nificant reduction in blood flow was noted in the 
arteries treated with fibrin sealant dressings, and 
there was no evidence of vessel thrombosis. Similar 
dressings are being commercially developed and may 
prove to be useful in a variety of clinical settings. Our 
data suggest that such dressings may have an applica- 
tion in elective vascular surgery and vascular trauma. 
Additional preclinical and clinical studies are recom- 
mended to further evaluate the broader range of 
potential applications. 
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